Comparison of Urinary Biomarkers in Diagnosis of Ureteropelvic Junction Obstruction and Differentiation from Nonobstructive Dilatation.

Background and Aims: Differentiation of nonobstructive dilatation (NOD) from ureteropelvic junction obstruction (UPJO) is a challenge in children with antenatally detected hydronephrosis. The aim of this study is to compare the utility of urinary biomarkers: carbohydrate antigen (CA 19-9), neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule (KIM) in diagnosing UPJO. Methods: A prospective study was conducted after obtaining ethical clearance between 2021 and 2022. Group 1 - control group (n = 30): children with normal antenatal ultrasound with no urinary symptoms. Group 2 - study group (n = 48): children with unilateral hydronephrosis: Group 2a - NOD (n = 24): children stable on ultrasound and diuretic renogram and Group 2b - UPJO (n = 24): children who worsened to Grade 4 hydronephrosis on ultrasound/worsening of differential renal function (10% drop) on renogram who underwent pyeloplasty. Urinary biomarkers NGAL, KIM-1, and CA 19-9 were measured using the enzyme-linked immune absorbent assay method. Results: The urine CA 19-9 level was 128.05 ± 4.08 U/mL in the UPJO group, and this was significantly higher (P = 0.001) than NOD, 70.29 ± 4.41, and controls, 1.91 ± 1.57. The urine NGAL level was 21.41 ± 4.44 pg/mL in UPJO, and this was significantly higher than controls, 2.669 ± 0.513, but not NOD, 24.55 ± 2.67. The urine KIM level was 817 ± 15.84 pg/mL in the UPJO group, and this was significantly higher than controls, 285 ± 8.10, but not NOD, 768.23 ± 15.12. Receiver operating characteristic analysis of CA 19-9 revealed a urine biomarker cutoff of 95 U/mL for diagnosing UPJO (sensitivity 95%; specificity 96%; and area under the curve 0.99). Conclusions: CA 19-9 is a superior marker compared to NGAL and KIM in differentiating UPJO from NOD. Further studies with larger numbers are warranted.

A Wearable Pendant Sensor to Monitor Compliance with Range of Motion Lymphatic Health Exercise.

Lymphedema is a chronic and debilitating condition affecting 1 in 1000 Americans and there is no known cure for it. The optimal lymph flow (TOLF) is an effective preventive exercise program designed to reduce the risks of lymphedema. This paper proposes a portable and wearable medical device to monitor compliance with the TOLF therapy. Specifically, the wearable pendant sensor (WPS), a low-fidelity prototype of the proposed design, is developed and tested in comparison with a markerless optical motion capture system (Kinect) for measurement accuracy during shoulder abduction-adduction and flexion-extension exercises. It is shown that the Kendall's Tau between the measurements obtained from the WPS and Kinect devices yields a correlation coefficient ρ = 0.807 for abduction-adduction exercise and ρ = 0.783 for flexion-extension exercise with a significance level of p < 0.001, indicating a strong correlation and high statistical significance. Following careful clinical assessment and validation, preliminary engineering design of this paper can be transformed into an Internet of Things (IoT)-based medical device to facilitate telemonitoring of TOLF therapy. Deployment of such an IoT-based device in patient homes can permit remote assessment of motor function to enhance treatment adherence.Clinical Relevance-This paper documents a WPS with potential to render an IoT-based medical device for monitoring adherence to TOLF exercise program to prevent the risk of post-operative lymphedema.